Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13D Filing: Bay City Capital Fund V, L.P. and Sunesis Pharmaceuticals Inc (SNSS)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
BAY CITY CAPITAL FUND V 0 1,828,968 0 1,828,968 1,828,968 5.3%
BAY CITY CAPITAL FUND V CO-INVESTMENT FUND 0 1,828,968 0 1,828,968 1,828,968 5.3%
BAY CITY CAPITAL MANAGEMENT V 1,828,968 0 1,828,968 0 1,828,968 5.3%
BAY CITY CAPITAL 1,828,968 0 1,828,968 0 1,828,968 5.3%

Page 1 of 13 – SEC Filing



Washington, D.C. 20549




Under the Securities Exchange Act of 1934

(Amendment No. 5)*



Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)


(CUSIP Number)

Susan Vuong

Chief Financial Officer

Bay City Capital LLC

Battery Street, Suite 400

San Francisco, California 94111

(415) 676-3830

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

October 27, 2017

(Date of Event Which Requires Filing of This Statement)



If the filing person has
previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following
box.  ☐

Follow Sunesis Pharmaceuticals Inc (NASDAQ:SNSS)
Trade (NASDAQ:SNSS) Now!